Takeda Touts Oral Triplet Regimen With Velcade Follow-On MLN9708
This article was originally published in The Pink Sheet Daily
Results from the FIRST study of long-term treatment with Celgene’s Revlimid/dexamethasone duo were well-received at the ASH meeting. Takeda believes adding on its oral proteasome inhibitor MLN9708 to form a trio could further improve outcomes and is actively evaluating a role for maintenance in pivotal trials, following encouraging Phase I/II results.
You may also be interested in...
The addition of Onyx’s cancer drugs to Amgen’s portfolio will fill a near-term sales gap for the big biotech and reinforce the company as a major oncology player. But Amgen will need to execute expertly on the merger if it is to transform itself into a high-growth biotech.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.